Recombinant Human CD30 Ligand/TNFSF8 Protein, CF | R&D Systems 1028-CL-050 product information

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human CD30 Ligand/TNFSF8 Protein, CF

catalog :

1028-CL-050

quantity :

50 ug

price :

294 USD

more info or order :

R&D Systems product webpage

citations: 7

Reference
Yeste Velasco M, Guo T, Mao X, Stankiewicz E, Scandura G, Li H, et al. The potential of brentuximab vedotin, alone or in combination with current clinical therapies, in the treatment of testicular germ cell tumors. Am J Cancer Res. 2019;9:855-871 pubmed
Clarke A, Poulton L, Shim D, Mabon D, Butt D, Pollard M, et al. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease. MAbs. 2018;10:664-677 pubmed publisher
Wilson T, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487:505-9 pubmed publisher
Simhadri V, Hansen H, Simhadri V, Reiners K, Bessler M, Engert A, et al. A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cells. Biol Chem. 2012;393:101-6 pubmed publisher
Suzuki O, Hirsch B, Abe M, Dürkop H, Stein H. Galectin-1-mediated cell death is increased by CD30-induced signaling in anaplastic large cell lymphoma cells but not in Hodgkin lymphoma cells. Lab Invest. 2012;92:191-9 pubmed publisher
Lobito A, Ramani S, Tom I, Bazan J, Luis E, Fairbrother W, et al. Murine insulin growth factor-like (IGFL) and human IGFL1 proteins are induced in inflammatory skin conditions and bind to a novel tumor necrosis factor receptor family member, IGFLR1. J Biol Chem. 2011;286:18969-81 pubmed publisher
Schwertassek U, Balmer Y, Gutscher M, Weingarten L, Preuss M, Engelhard J, et al. Selective redox regulation of cytokine receptor signaling by extracellular thioredoxin-1. EMBO J. 2007;26:3086-97 pubmed

product information

brand :

R&D Systems, a Bio-Techne Brand

catalog number base :

1028-CL

SKU :

1028-CL-050

product name :

Recombinant Human CD30 Ligand/TNFSF8 Protein, CF

Description :

The Recombinant Human CD30 Ligand/TNFSF8 Protein, CF from R&D Systems is derived from NS0. The Recombinant Human CD30 Ligand/TNFSF8 Protein, CF has been validated for the following applications: Bioactivity.

target :

CD30 Ligand/TNFSF8

category :

Proteins and Enzymes

unit size :

50 ug

buffer :

Lyophilized from a 0.2 µm filtered solution in PBS.

conjugate :

Unconjugated

purity :

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

species :

Human

observed molecular weight :

30-40 kDa, reducing conditions

theoretical molecular weight :

22 kDa

gene symbol :

TNFSF8

details of functionality :

Measured by its ability to stimulate IL-6 secretion by HDLM human Hodgkin’s lymphoma cells. Duckett, C.S. et al . (1997) Mol. Cell. Biol. 17 :1535. The ED50 for this effect is 8-48 ng/mL in the presence of 10 µg/mL of a cross-linking antibody, Mouse Anti-polyHistidine Monoclonal Antibody (Catalog # MAB050 ).

endotoxin note :

<0.10 EU per 1 µg of the protein by the LAL method.

accessionNumbers :

P32971

applications :

Bioactivity

source :

NS0-derived Recombinant Human CD30 Ligand/TNFSF8 Protein

USD :

294 USD

alt names :

CD153, CD153 antigen, CD30 antigen ligand, CD30L, CD30-L, CD30LCD30 ligand, CD30LGMGC138144, TNFSF8, tumor necrosis factor (ligand) superfamily, member 8, tumor necrosis factor ligand superfamily member 8

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage